Lucid Diagnostics Inc (LUCD) is a Healthcare · Medical Devices company listed on NASDAQ. Price $0.77 (-1.67%), Market cap $0.19B, 52-week low–high $0.96 ~ $1.59.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAV
Financial statements, price targets, institutional (13F) holdings and related news for Lucid Diagnostics Inc are updated in real time on BlackAll Trade.
Lucid Diagnostics Inc trades at $0.77 (-1.67%). Real-time quotes and charts are available on BlackAll Trade.
Lucid Diagnostics Inc has a market cap of about $0.19B.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of